dence for the management of ENL.Trial registration numberNCT 03775460.The number of people that have one or multiple condition(s) with a chronic course is rising, which consequently challenges healthcare systems. Healthcare geared to long-term care should focus on patient-centredness, shared decision making and self-management. https://www.selleckchem.com/products/primaquine.html The Assessment of Burden of Chronic Conditions (ABCC) tool was developed to integrate these elements in daily healthcare practice. The ABCC tool assesses and visualises burden of disease(s), helps to make shared decisions and stimulates self-management. The present paper documents a protocol for a quasi-experimental study investigating the effectiveness and cost-effectiveness of the ABCC tool for people with chronic obstructive pulmonary disease, asthma, type 2 diabetes mellitus and/or heart failure.
The study has a pragmatic clustered quasi-experimental design and will be conducted in the Netherlands. The intervention will be allocated at the level of general practice. The intervention group (18 general practices, 180 patients) will use the ABCC tool during regular consultations; the control group (18 general practices, 180 patients) will maintain usual care. Outcomes include change in quality of care (Patient Assessment of Chronic Illness Care), quality of life (EuroQol-5D-5L), capability well-being (ICEpop CAPability measure for Adults), patients' activation (Patient Activation Measure) and costs. Follow-up time will be 18 months. Outcomes will be analysed using linear mixed models.
Ethical approval was obtained from the Medical Ethics Committee Zuyderland-Zuyd Heerlen, the Netherlands (METCZ20180131). Results will be published in peer-reviewed journals and will be presented at national and international conferences.
ClinicalTrials.gov Registry (NCT04127383).
ClinicalTrials.gov Registry (NCT04127383).is the most well-known risk factor for gastric cancer. At present, shows varying levels of resistance to different treatments, leading to a lower rate of eradication. The aim of this study is to evaluate the efficacy of polaprezinc-containing quadruple therapy (PQT) for the eradication of infection and, thus, to provide more evidence to inform the clinical treatment of infection in China.
This is a single-centre, single-blind, non-inferiority, randomised controlled trial, enrolling 158 patients with infection. Patients are randomised (11) to the two groups for a 14-day therapy. Treatment group PQT (esomeprazole 20?mg, amoxicillin 1?g, clarithromycin 500?mg, polaprezinc 75?mg) two times per day; control group bismuth-containing quadruple therapy (esomeprazole 20?mg, amoxicillin 1?g, clarithromycin 500?mg, bismuth potassium citrate 220?mg) two times per day. The primary outcome is the rate of eradication. Secondary outcomes are the incidence of adverse events and the gastrointestinal microbiota distribution. The 16S ribosomal RNA (16S rRNA) next-generation sequencing (NGS) is used to evaluate the effect of two different therapies on the distribution of the gastrointestinal microbiota.
This study was approved by the Ethics Committee of Sichuan Cancer Center &amp; Hospital (No. SCCHEC-02-2019-015). Any amendment to the research protocol will be submitted for ethical approval. All participants must provide informed consent. On completion, the results of the study will be published in the appropriate peer-reviewed journal.
ChiCTR1900025800; preresults.
ChiCTR1900025800; preresults.We developed an informational support questionnaire of transitional care (ISQTC) for aged patients with chronic disease and investigated its reliability and validity.
This study was conducted in three large general hospitals in Nantong, Jiangsu Province, China.
A total of 130 aged patients with chronic diseases, admitted into outpatient and inpatient departments from three hospitals in China, participated in the study. The inclusion criteria were (1) patients must provide consent to participate; (2) being 60 years and above; (3) being diagnosed with at least one chronic disease and hospitalised more than two times within the last 1?year; (4) being able to listen, speak, read and write. The exclusion criteria were (1) refusing to participate; (2) language expression and communication barriers (and having no caregiver to assist in participation); (3) being in intensive care or long-term hospitalisation.
The developed questionnaire was validated and tested for reliability. The content validity of the questionnaire was determined through experts' interviews and Delphi expert consultation, and the structure validity of the questionnaire was determined by performing exploratory factor analysis. The coefficient of reliability of the questionnaire was measured using Cronbach's alpha.
Through Delphi expert consultation and exploratory factor analysis, the questionnaire was reduced from four dimensions and 12 items to three dimensions and 11 items. A total of 130 patients responded to the questionnaire. The alpha coefficient was 0.747.
The ISQTC is a reliable and valid instrument for evaluating aged patients with chronic disease in transitional care.
ChiCTR1900020923. The trial was registered on 22 January 2019.
ChiCTR1900020923. The trial was registered on 22 January 2019.Environmental enteropathy (EE) is suspected to be a cause of growth faltering in children with sustained exposure to enteric pathogens, typically in resource-limited settings. A major hindrance to EE research is the lack of sensitive, non-invasive biomarkers. Current biomarkers measure intestinal permeability and inflammation, but not the functional capacity of the gut. Australian researchers have demonstrated proof of concept for an EE breath test based on using naturally C-enriched sucrose, derived from maize, to assay intestinal sucrase activity, a digestive enzyme that is impaired in villus blunting. Here, we describe a coordinated research project to optimise, validate and evaluate the usability of a breath test protocol based on highly enriched C-sucrose to quantify physiological dysfunction in EE in relevant target populations.
We use the C-sucrose breath test (C-SBT) to evaluate intestinal sucrase activity in two phases. First, an optimisation and validation phase will (1) confirm that a C-SBT using highly enriched sucrose tracers reports similar information to the naturally enriched C-SBT; (2) examine the dose-response relationship of the test to an intestinal sucrase inhibitor; (3) validate the C-SBT in paediatric coeliac disease (4) validate the highly enriched C-SBT against EE defined by biopsy in adults and (5) validate the C-SBT against EE defined by the urinary lactuloserhamnose ratio (LR) among children in Peru.